(Bloomberg) — Lyell Immunopharma Inc., a cancer drug developer backed by GlaxoSmithKline Plc and Celgene Corp., seesawed in its trading debut after raising $425 million in an initial public offering.

The shares opened up 10% from the $17 IPO price and then fell as much as 12% Thursday in New York trading. They closed down 0.7% to $16.89, giving the company a market value of about $4.1 billion. Lyell sold 25 million shares Wednesday after marketing them for $16 to $18.

The California company, based in South San Francisco, was founded in 2018 by Rick Klausner, former director of the National Cancer Institute and the co-founder of Juno Therapeutics Inc., according to Lyell’s filings. Lyell describes itself as “a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors.”

Lyell, doesn’t have any products on the market, said it expects to incur substantial losses for the foreseeable future. It had a net loss of $204 million on revenue of $7.8 million last year, according to its filing.

The offering was led by Goldman Sachs Group Inc., Bank of America Corp., JPMorgan Chase & Co. and Morgan Stanley. The shares are trading on the Nasdaq Global Market under the symbol LYEL.

(Updates with closing share price in second paragraph)

More stories like this are available on bloomberg.com

Subscribe now to stay ahead with the most trusted business news source.

©2021 Bloomberg L.P.

(305) 707 0888